A Phase 2, Multicenter, International Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Trial Profile

A Phase 2, Multicenter, International Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 03 Jun 2017 This trial has been completed in Spain (end date: 20 Apr 2017).
    • 28 May 2017 This trial has been completed in Spain (end date: 20 Apr 2017).
    • 05 Apr 2017 Planned End Date changed from 1 Mar 2017 to 15 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top